Trademark Infringement in Pharmaceutical Portmanteau Marks: Schering Corporation v. Getwell Life Sciences India Pvt. Ltd.

Introduction

The case of Schering Corporation v. Getwell Life Sciences India Pvt. Ltd. was adjudicated by the Delhi High Court on July 4, 2008. This litigation centered on allegations of trademark infringement involving pharmaceutical products, specifically focusing on the use of portmanteau marks. The plaintiffs, Schering Corporation and its predecessor, held registered trademarks for 'TEMODAL' and 'TEMODAR', which were associated with the drug Temozolomide—a treatment for brain cancer. The defendants, Getwell Life Sciences India Pvt. Ltd., introduced a product under the mark 'TEMOGET', leading to the contention over potential trademark infringement.

Summary of the Judgment

The Delhi High Court examined whether the defendant's mark 'TEMOGET' infringed upon the plaintiffs' registered trademarks 'TEMODAL' and 'TEMODAR'. The court considered factors such as the similarity of the marks, the distinctiveness of the prefixes, the nature of the pharmaceutical industry, and the practical aspects of product usage and pricing. Ultimately, the court concluded that there was no deceptive similarity between the marks. The defendant's mark was deemed to be distinguishable, and considerations like significant price differences and controlled distribution methods further mitigated the risk of consumer deception. Consequently, the court dismissed the plaintiffs' application for an interim injunction, favoring the defendant's continued use of the 'TEMOGET' mark.

Analysis

Precedents Cited

The judgment extensively referenced several precedents to bolster its reasoning:

• Astrazeneca UK Ltd. & Anr. v. Orchid Chemicals & Pharmaceuticals Ltd. (2007): Addressed trademark similarity in pharmaceuticals, emphasizing the common use of prefixes related to chemical compounds.
• Heinz Italia and Anr. v. Dabur India Ltd. (2007): Dealt with passing off, differentiating it from trademark infringement.
• Bhagwan Dass Gupta v. Shiv Shankar Tirath Yatra Co. Pvt. Ltd. (2001): Discussed the concept of 'publici juris' in trademarks.
• Milmet Oftho Industries & Ors. v. Allergan Inc. (2004): Highlighted factors like product form and pricing in assessing deception.
• Pfizer Ireland Pharmaceuticals v. Intas Pharmaceuticals & Anr. (2004): Focused on passing off rather than direct trademark infringement.
• Hoechst Pharmaceuticals Ltd. & Ors. v. Government of India & Ors. (1983): Discussed the therapeutic value differences in pharmaceuticals.
• Ramdev Food Products (P) Ltd. v. Arvindbhai Rambhai Patel & Ors. (2006): Examined the assumption of product quality in trademark cases.

Legal Reasoning

The court's legal reasoning was multifaceted:

• Publici Juris: The prefix 'TEMO' was deemed to be derived from the generic term 'Temozolomide', making it publici juris. This meant that 'TEMO' could not be exclusively claimed by the plaintiffs.
• Portmanteau Words: Both parties used portmanteau marks—blending 'TEMO' with distinct suffixes ('DAL', 'DAR', 'GET'). The court analyzed these combinations to assess visual and phonetic similarities.
• Deceptive Similarity: The court evaluated whether 'TEMOGET' was likely to deceive consumers into associating it with 'TEMODAL' or 'TEMODAR'. Factors such as distinct suffixes, significant price differences, and controlled distribution avenues reduced the potential for deception.
• Product Usage and Distribution: Temozolomide being a Schedule 'H' drug meant it was sold only via prescription, limiting casual consumer confusion. Additionally, the significant price disparity between 'TEMOGET' and the plaintiffs' products further diminished the likelihood of deception.
• Precedent Alignment: The court aligned its decision with the Astrazeneca case, emphasizing that shared generic prefixes in pharmaceuticals do not necessarily lead to trademark infringement.

Impact

This judgment holds significant implications for the pharmaceutical industry, particularly concerning naming conventions for drugs:

• Trademark Registration: Emphasizes that generic terms derived from chemical compounds cannot be exclusively owned, preventing monopolization over commonly used prefixes.
• Portmanteau Usage: Encourages the use of unique suffixes in portmanteau trademarks to maintain distinctiveness and avoid confusion.
• Pricing and Distribution: Highlights the role of pricing strategies and controlled distribution in mitigating potential trademark disputes.
• Future Litigation: Provides a clear framework for assessing trademark infringement in cases involving generic prefixes, guiding future legal decisions in similar contexts.

Complex Concepts Simplified

Publici Juris

Publici juris refers to terms or expressions that are so commonly used or are generic that they cannot be owned exclusively by any entity. In this case, 'TEMO' is derived from 'Temozolomide', making it a publici juris term.

Portmanteau Words

Portmanteau words are linguistic blends formed by combining parts of two or more words. Examples include 'brunch' (breakfast + lunch) and 'spanglish' (Spanish + English). In the pharmaceutical context, portmanteau marks often combine a generic drug name with a unique suffix to create a distinctive brand.

Deceptive Similarity

Deceptive similarity occurs when one trademark is so similar to another that consumers are likely to be confused or misled about the source of the goods or services. Factors influencing this include visual and phonetic likeness, product similarity, and the context of use.

Conclusion

The Delhi High Court's decision in Schering Corporation v. Getwell Life Sciences India Pvt. Ltd. underscores the nuanced approach required in trademark infringement cases within the pharmaceutical sector. By recognizing the generic nature of certain terms and evaluating the distinctiveness of portmanteau marks, the court balanced the plaintiffs' trademark rights with the defendants' legitimate use of common drug nomenclature. This judgment serves as a precedent for future cases, emphasizing that the exclusivity of generic prefixes is limited and that factors such as mark distinctiveness, product differentiation, and market practices play crucial roles in determining infringement.